MA53881A - Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 - Google Patents
Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2Info
- Publication number
- MA53881A MA53881A MA053881A MA53881A MA53881A MA 53881 A MA53881 A MA 53881A MA 053881 A MA053881 A MA 053881A MA 53881 A MA53881 A MA 53881A MA 53881 A MA53881 A MA 53881A
- Authority
- MA
- Morocco
- Prior art keywords
- idh1
- oxazin
- pyrido
- inhibitors
- derivatives
- Prior art date
Links
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 title 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 title 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 title 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 title 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- UAQLXVHFTVTPBK-UHFFFAOYSA-N pyrido[4,3-d][1,3]oxazin-2-one Chemical class N=1C(OC=C2C=1C=CN=C2)=O UAQLXVHFTVTPBK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435283P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53881A true MA53881A (fr) | 2022-04-27 |
Family
ID=60888651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053881A MA53881A (fr) | 2016-12-16 | 2017-12-08 | Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 |
| MA47399A MA47399B1 (fr) | 2016-12-16 | 2017-12-08 | Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47399A MA47399B1 (fr) | 2016-12-16 | 2017-12-08 | Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 |
Country Status (37)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3194375B1 (en) | 2014-09-19 | 2018-11-21 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9771349B2 (en) | 2014-09-19 | 2017-09-26 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| PT3733662T (pt) | 2014-09-19 | 2023-08-18 | Forma Therapeutics Inc | Derivados piridin-2(1h)-ona-quinolinona como inibidores de isocitrato desidrogenase mutante |
| ES2768694T3 (es) | 2014-09-19 | 2020-06-23 | Forma Therapeutics Inc | Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| PT3433256T (pt) | 2016-10-24 | 2019-10-31 | Astrazeneca | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento do cancro |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| ES2922379T3 (es) | 2016-12-16 | 2022-09-14 | Janssen Pharmaceutica Nv | Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas |
| CN110072867B (zh) * | 2016-12-16 | 2022-07-08 | 伊莱利利公司 | 作为突变体idh1和idh2抑制剂的7-苯基乙基氨基-4h-嘧啶并[4,5-d][1,3]噁嗪-2-酮化合物 |
| KR102246668B1 (ko) | 2017-01-30 | 2021-04-29 | 아스트라제네카 아베 | 에스트로겐 수용체 조절인자 |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| EP3720442B1 (en) | 2018-05-16 | 2022-12-28 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| JP7744336B2 (ja) * | 2019-11-08 | 2025-09-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ｇｅｍ－二置換複素環式化合物及びＩＤＨ阻害剤としてのその使用 |
| EP4125917B1 (en) | 2020-03-23 | 2024-04-17 | Eli Lilly and Company | Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor |
| IL296094A (en) | 2020-03-23 | 2022-11-01 | Lilly Co Eli | Method for treating idh1 inhibitor-resistant subjects |
| BR112022017394A2 (pt) | 2020-03-23 | 2022-10-18 | Lilly Co Eli | Terapia de combinação com um inibidor de idh mutante |
| IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| PE20221838A1 (es) | 2020-04-24 | 2022-11-29 | Astrazeneca Ab | Formulaciones farmaceuticas |
| US20230174550A1 (en) * | 2020-06-28 | 2023-06-08 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Idh mutant inhibitor and use thereof |
| WO2022020281A1 (en) | 2020-07-20 | 2022-01-27 | Eli Lilly And Company | Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent |
| AU2022233254A1 (en) | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| CN113588768B (zh) * | 2021-05-18 | 2022-07-05 | 国家卫生健康委科学技术研究所 | 一种以分子图像方式定量组织内内源性代谢物的质谱方法 |
| EP4337217A1 (en) | 2021-06-09 | 2024-03-20 | Eli Lilly and Company | Method for treating idh inhibitor-resistant subjects |
| BR112023024454A2 (pt) * | 2021-06-15 | 2024-02-06 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero |
| US11746115B2 (en) | 2021-08-13 | 2023-09-05 | Eli Lilly And Company | Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one |
| WO2023141087A1 (en) | 2022-01-19 | 2023-07-27 | Eli Lilly And Company | Combination therapy with a mutant idh inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6026544B2 (ja) * | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| KR20150127197A (ko) * | 2013-03-14 | 2015-11-16 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| US10294206B2 (en) * | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10471507B2 (en) * | 2015-04-24 | 2019-11-12 | Halliburton Energy Services, Inc. | Methods of fabricating ceramic or intermetallic parts |
| WO2017019429A1 (en) * | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| ES2814290T3 (es) * | 2016-06-06 | 2021-03-26 | Lilly Co Eli | Inhibidores de IDH1 mutante |
| CN110072867B (zh) * | 2016-12-16 | 2022-07-08 | 伊莱利利公司 | 作为突变体idh1和idh2抑制剂的7-苯基乙基氨基-4h-嘧啶并[4,5-d][1,3]噁嗪-2-酮化合物 |
-
2017
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/en not_active Ceased
- 2017-12-08 HR HRP20201882TT patent/HRP20201882T1/hr unknown
- 2017-12-08 CA CA3045303A patent/CA3045303C/en active Active
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/en active Active
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 MX MX2019006830A patent/MX385562B/es unknown
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/en active Active
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
-
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
-
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
-
2021
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53881A (fr) | Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 | |
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| MA46470A (fr) | 1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MX390630B (es) | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. | |
| IL263947A (en) | Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof | |
| MX386328B (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| HUE053027T2 (hu) | Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra | |
| EP3416964A4 (en) | Carboxamide derivatives as RSK inhibitors | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| MA46264A (fr) | Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire | |
| ME03672B (me) | 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori | |
| EP3328379A4 (en) | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF THE PROTEIN AGGREGATION | |
| EP3380475A4 (en) | OCTAHYDROPYRROLO [3,4-C | |
| MA54448A (fr) | Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5 | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| EP3334719A4 (en) | SUBSTITUTED BENZIMIDAZOLE, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | |
| MA52722A (fr) | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| MA47593A (fr) | Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase | |
| EP3487851A4 (en) | AMINOPYRIDE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | |
| MA54101A (fr) | Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation | |
| EP3402793A4 (en) | Pyridazine derivatives as EAAT2 activators | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |